Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout. This is a multi-center, double-blind, randomized, parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of...
Brief Summary
Official Title: “A 1-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel Trial Comparing Lumiracoxib (400 mg Once Daily) in Patients With Acute Flares of Gout, Using Indomethacin (50 mg Three Times a Day)”
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout. This is a multi-center, double-blind, randomized, parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of efficacy
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: Lumiracoxib
Outcome Measures for this Clinical Trial
Primary Measures
- Pain intensity in the study joint over days 2 to 5 approximately 4h after the first daily dose
Secondary Measures
- Safety and tolerability profile
- Pain intensity in the study joint over the entire treatment period
- Patient’s and Physician’s global assessment of response to therapy
- Physician’s assessment of tenderness and swelling of study joint
- C-reactive protein level
- Proportion of patients who discontinued treatment because of a lack of efficacy
- Usage of rescue medication
- SF-36 and EQ-5D
- Physician’s assessment of erythema of study joint
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Ambulatory cooperative male or female patients of at least 18 years of age
- With an acute attack of gout in 4 joints or less, diagnosed clinically according to the ACR 1977 classification criteria and with an onset within the last 48 hours prior to evaluation. Where more than one joint is involved, the most affected joint should be identified, as the study joint, at baseline and followed throughout the study
- Who present at Baseline with an acute pain intensity of at least moderate.
Exclusion Criteria:
- With an acute attack of gout before the last 48 hours prior to evaluation
- With polyarticular gout involving > 4 joints
- With rheumatoid arthritis, infectious arthritis, pseudo-gout or other acute inflammatory arthritides.
- Other protocol-defined inclusion/exclusion criteria may apply.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Novartis Industry
Overall Clinical Trial Officials and Contacts
Novartis Pharma AG Study Chair Sponsor GmbH
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00170781
Study ID Number: CCOX189A2426
ClinicalTrials.gov Identifier: NCT00170781
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00170781
